Oral Antibiotic Regimen for Outpatient Wound Infections
For most outpatient wound infections, amoxicillin-clavulanate 875/125 mg twice daily is the first-line oral antibiotic, providing coverage against common aerobic and anaerobic pathogens 1.
Standard Coverage (Non-MRSA)
Amoxicillin-clavulanate remains the guideline-recommended oral agent for wound infections requiring both aerobic and anaerobic coverage 1. This regimen effectively covers:
- Staphylococcus aureus (methicillin-susceptible)
- Streptococcus species
- Anaerobes
- Most common Gram-negative organisms
Important caveat: Some Gram-negative rods demonstrate resistance, and this regimen does not cover MRSA 1.
MRSA Coverage
When MRSA is suspected or confirmed, trimethoprim-sulfamethoxazole (TMP-SMX) 160-800 mg twice daily is the preferred oral agent based on its superior bactericidal activity 1, 2. Research demonstrates TMP-SMX achieves >2 log₁₀ cfu/mL decrease at 8 hours and >3 log₁₀ cfu/mL decrease at 24 hours—outperforming other oral options including linezolid, clindamycin, and minocycline 2.
Alternative MRSA options (in descending order of preference):
- Doxycycline 100 mg twice daily - good activity against MRSA, though some streptococci are resistant 1
- Clindamycin 300 mg three times daily - covers staphylococci, streptococci, and anaerobes but misses Pasteurella multocida 1
Critical warning: Increasing resistance patterns show MRSA resistance to clindamycin rose from 3.4% (2007) to 10% (2012), and TMP-SMX resistance increased from 3.5% to 6% over the same period 3. Despite this trend, TMP-SMX remains the most bactericidal oral option available.
Sulfa Allergy Alternatives
For patients with sulfa allergy requiring MRSA coverage:
Primary option: Doxycycline 100 mg twice daily 1
Secondary option: Clindamycin 300 mg three times daily 1
- Monitor for increasing resistance
- Consider D-test if available to rule out inducible clindamycin resistance
Enhanced Gram-Negative Coverage
When Gram-negative organisms are suspected (diabetic foot infections, contaminated wounds):
Fluoroquinolone monotherapy:
- Moxifloxacin 400 mg daily - provides both aerobic and anaerobic coverage as monotherapy 1
- Levofloxacin 750 mg daily - requires addition of metronidazole for anaerobic coverage 1
- Ciprofloxacin 500-750 mg twice daily - good Pasteurella coverage but misses MRSA and some anaerobes 1
Combination therapy for mixed infections:
- Ciprofloxacin or levofloxacin PLUS metronidazole 250-500 mg three times daily provides comprehensive aerobic and anaerobic coverage 1
Special Wound Types
Animal/human bites: Amoxicillin-clavulanate 875/125 mg twice daily is specifically recommended 1. For β-lactam allergy, use moxifloxacin 400 mg daily as single agent, or levofloxacin/ciprofloxacin plus metronidazole 1.
Diabetic foot infections: While amoxicillin-clavulanate provides baseline coverage, consider that MRSA prevalence in diabetic wounds ranges 5-30% 4. If MRSA suspected, add TMP-SMX or switch to moxifloxacin for broader coverage.
Critical Clinical Pitfalls
Do not combine TMP-SMX with rifampin - research shows a trend toward antagonism rather than synergy 2
Avoid first-generation cephalosporins for bite wounds - they miss Eikenella corrodens, a common human bite pathogen resistant to cephalexin, macrolides, and clindamycin 1
Culture before treating when possible - no current oral agent reliably covers both MRSA and relevant Gram-negative pathogens simultaneously 5, making empiric therapy potentially inadequate for polymicrobial infections
Second-generation cephalosporins (cefuroxime 500 mg twice daily) miss anaerobes despite good Pasteurella coverage 1
Treatment Duration
Standard duration is 7-10 days for most wound infections, though no evidence supports 10 days over 7 days for uncomplicated cases 6.